- Home
- NCTY vs HLVX Comparison
NCTY vs HLVX Comparison
Compare NCTY & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCTY
- HLVX
- Stock Information
- Founded
- NCTY 1999
- HLVX 2020
- Country
- NCTY China
- HLVX United States
- Employees
- NCTY N/A
- HLVX N/A
- Industry
- NCTY Business Services
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- NCTY Consumer Discretionary
- HLVX Health Care
- Exchange
- NCTY Nasdaq
- HLVX Nasdaq
- Market Cap
- NCTY 121.2M
- HLVX 104.3M
- IPO Year
- NCTY 2004
- HLVX 2022
- Fundamental
- Price
- NCTY $7.54
- HLVX $2.08
- Analyst Decision
- NCTY
- HLVX Hold
- Analyst Count
- NCTY 0
- HLVX 1
- Target Price
- NCTY N/A
- HLVX $2.00
- AVG Volume (30 Days)
- NCTY 36.9K
- HLVX 829.7K
- Earning Date
- NCTY 01-01-0001
- HLVX 08-06-2025
- Dividend Yield
- NCTY N/A
- HLVX N/A
- EPS Growth
- NCTY N/A
- HLVX N/A
- EPS
- NCTY N/A
- HLVX N/A
- Revenue
- NCTY $15,305,175.00
- HLVX N/A
- Revenue This Year
- NCTY N/A
- HLVX N/A
- Revenue Next Year
- NCTY N/A
- HLVX N/A
- P/E Ratio
- NCTY N/A
- HLVX N/A
- Revenue Growth
- NCTY N/A
- HLVX N/A
- 52 Week Low
- NCTY $6.28
- HLVX $1.34
- 52 Week High
- NCTY $20.59
- HLVX $2.17
- Technical
- Relative Strength Index (RSI)
- NCTY 36.34
- HLVX 52.92
- Support Level
- NCTY $7.41
- HLVX $2.07
- Resistance Level
- NCTY $8.42
- HLVX $2.10
- Average True Range (ATR)
- NCTY 0.62
- HLVX 0.04
- MACD
- NCTY -0.12
- HLVX -0.01
- Stochastic Oscillator
- NCTY 6.70
- HLVX 50.00
About NCTY The9 Limited American Depository Shares
The9 Ltd operates a cryptocurrency mining business. It provides computing power, or hash rate, to a Bitcoin mining pool and is entitled to receive a fractional share of Bitcoin award from the Bitcoin mining pool in return. The company generates its revenues from customers in Greater China, Asia/Eastern Europe, and North America. Its segments are: Crypto mining business, and Other, out of which Crypto mining business derives maximum revenue.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.